(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 15.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Mirum Pharmaceuticals's revenue in 2025 is $471,794,000.On average, 12 Wall Street analysts forecast MIRM's revenue for 2025 to be $26,625,468,882, with the lowest MIRM revenue forecast at $25,384,314,070, and the highest MIRM revenue forecast at $27,575,222,130. On average, 12 Wall Street analysts forecast MIRM's revenue for 2026 to be $31,927,229,976, with the lowest MIRM revenue forecast at $28,915,052,604, and the highest MIRM revenue forecast at $35,594,675,417.
In 2027, MIRM is forecast to generate $37,821,045,042 in revenue, with the lowest revenue forecast at $32,901,138,203 and the highest revenue forecast at $43,062,675,655.